ABOUT MiNA
Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases.
PIONEERING NEW CLASS OF MEDICINES
Small activating RNAs are an entirely new class of medicines with potential to offer transformational benefits to patients across a wide range of diseases.
CLINICAL STAGE PLATFORM
We have developed a systematic approach to take new saRNA medicines from an idea to patients in a clinical trial in just 2 years.
EXPERIENCED TEAM
Driving our platform are a group of passionate scientists, drug developers, doctors and entrepreneurs shaped by experience in oligonucleotide therapeutics, cancer and liver diseases.
TWITTER FEED
Follow us on Twitter
Prof Habib and Dr Sodergren presenting in the afternoon poster session #AACR2019
Poster 3586 | 1pm on Tue Apr 2 | Experimental and Molecular Therapeutics – Novel Antitumour Agents 2 | MTL-CEBPA, a drug candidate for hepatocellular carcinoma enhances efficacy of sorafenib #AACR2019
Poster 3211 | 8am on Tue Apr 2 | Immunology – Combination Immunotherapies 2 | MTL-CEBPA combined with radiofrequency ablation and immunotherapy enhances immunological anti-tumour responses in an HCC mouse model #AACR2019
We're excited to present 2 posters today at #AACR209 showing immunological and anti-tumour effects of MTL-CEBPA in combination with standard of care treatments in pre-clinical models of liver cancer
Latest research from Rossi lab .@cityofhope on anti-inflammatory effects of MTL-CEBPA in mouse model of sepsis published in #MolecularTherapy